Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Lizhu Lin et al.|The Lancet Respiratory Medicine|2020Cited by 504
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activationZhen Qin, Hongbin Ji, Meiting Yue et al.|The Journal of Experimental Medicine|2024Cited by 21